Understanding Factor XIII: A Potential Drug Target for Blood Clots

Target Name: Coagulation Factor XIII

NCBI ID: P46614

Coagulation Factor XIII

Other Name(s): Factor XIII

Understanding Factor XIII: A Potential Drug Target for Blood Clots

Coagulation Factor XIII (Factor XIII), also known as prothrombin complex III (PCCI3), is a protein that plays a critical role in the body's clotting mechanism. It is one of the eight proteins that make up the prothrombin complex, which is responsible for generating the active ingredient of blood clots called thrombin. When a cut or injury occurs in the body, the prothrombin complex is activated and converts prothrombin into factor XIII, which then works with other proteins to form a blood clot and help stop bleeding.

Unlike many other proteins, factor XIII is not a drug target or biomarker. There is no known cure for factor XIII deficiency, and it is not widely used in drug development. However, the study of factor XIII and its role in the body's clotting mechanism is an active area of 鈥嬧?媟esearch, and there is a growing interest in developing new treatments for blood clots and other conditions that involve the prothrombin complex.

One approach to studying factor XIII is through the use of genetic engineering techniques. Researchers have used CRISPR-Cas9 to modify the genes of animals and create new proteins that contain different versions of the factor XIII gene. These modified proteins have been shown to have different properties and functions than the original protein, and some have been shown to be more effective at forming blood clots than others.

Another approach to studying factor XIII is through the use of its role as a drug target. Several researchers have identified potential drug targets for factor XIII, including the protein's structure, its role in the body's clotting mechanism, and its interaction with other proteins. One potential drug target is the protein's interaction with the protein thrombex, which is also known as thrombin. Researchers have shown that inhibiting thrombin's activity with small molecules can be an effective way to prevent blood clots.

In addition to its potential as a drug target, factor XIII is also of interest to researchers because of its role in the body's clotting mechanism. Understanding how factor XIII works can provide insights into the underlying mechanisms of blood clots and other conditions that involve the prothrombin complex. This can lead to the development of new treatments and therapies for these conditions.

Overall, the study of factor XIII is an important area of 鈥嬧?媟esearch that has the potential to lead to new treatments and therapies for a variety of conditions. While the protein itself is not a drug target or biomarker, the study of its role in the body's clotting mechanism is an active area of 鈥嬧?媟esearch that can lead to new insights and treatments.

Protein Name: Coagulation Factor XIII

The "Coagulation Factor XIII Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Coagulation Factor XIII comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets